Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KURA
STRONG SELLKura Oncology, Inc. · Healthcare · United States · $922M · Avg Vol: $16M/d
COMPANY DESCRIPTION
Kura Oncology is a clinical-stage biotechnology company dedicated to discovering and developing precision medicines for cancer, particularly targeting farnesyl transferase and other cancer pathways. Its competitive edge lies in proprietary drug candidates with novel mechanisms of action and a pipeline addressing significant unmet needs in oncology. The company's lead candidate, ziftomenib, is in late-stage clinical trials for acute myeloid leukemia (AML).
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 53.9M | 67.5M | 25.2% | 71.6M | 95.0M | — | 40.8% |
| EPS | -2.03 | -2.08 | -2.02 | -3.18 | — | -3.29 | -3.44 | -2.58 | — |
| Shares | 68.3M | 74.3M | 78.2M | 87.9M | +28.6% | 88.8M | — | — | — |
| Debt | 14.0M | 17.2M | 16.6M | 20.5M | 13.4% | 24.3M | — | — | — |
| Equity | 420.3M | 397.3M | 413.6M | 174.1M | -25.4% | — | — | — | — |
| Op CF | -110.1M | -124.8M | 134.3M | -64.1M | — | -78.0M | — | — | — |
| Inv CF | 32.6M | 15.6M | -101.6M | -13.1M | — | — | — | — | — |
| Fin CF | 38.6M | 94.8M | 154.4M | 1.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KURA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KURA | Kura Oncology, Inc.(you) | $922M | 19 | STRONG SELL |
| PHAT | Phathom Pharmaceuticals, Inc. | $912M | 21 | SELL |
| SVRA | Savara Inc. | $1.1B | 19 | STRONG SELL |
| JANX | Janux Therapeutics, Inc. | $935M | 24 | SELL |
| ANNX | Annexon, Inc. | $855M | 16 | STRONG SELL |
| ACRS | Aclaris Therapeutics, Inc. | $730M | 21 | SELL |
| AVTX | Avalo Therapeutics, Inc. | $976M | 25 | SELL |
| ANL | Adlai Nortye Ltd. | $805M | 24 | SELL |
| ORIC | ORIC Pharmaceuticals, Inc. | $1.3B | 21 | SELL |
| VOR | Vor Biopharma Inc. | $1.0B | 14 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%